...
首页> 外文期刊>Critical care : >Clinical review: Fresh frozen plasma in massive bleedings - more questions than answers
【24h】

Clinical review: Fresh frozen plasma in massive bleedings - more questions than answers

机译:临床评论:大量出血中的新鲜冷冻血浆-问题多于答案

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Fresh frozen plasma (FFP) is indicated for the management of massive bleedings. Recent audits suggest physician knowledge of FFP is inadequate and half of the FFP transfused in critical care is inappropriate. Trauma is among the largest consumers of FFP. Current trauma resuscitation guidelines recommend FFP to correct coagulopathy only after diagnosed by laboratory tests, often when overt dilutional coagulopathy already exists. The evidence supporting these guidelines is limited and bleeding remains a major cause of trauma-related death. Recent studies demonstrated that coagulopathy occurs early in trauma. A novel early formula-driven haemostatic resuscitation proposes addressing coagulopathy early in massive bleedings with FFP at a near 1:1 ratio with red blood cells. Recent retrospective reports suggest such strategy significantly reduces mortality, and its use is gradually expanding to nontraumatic bleedings in critical care. The supporting studies, however, have bias limiting the interpretation of the results. Furthermore, logistical considerations including need for immediately available universal donor AB plasma, short life after thawing, potential waste and transfusion-associated complications have challenged its implementation. The present review focuses on FFP transfusion in massive bleeding and critically appraises the evidence on formula-driven resuscitation, providing resources to allow clinicians to develop informed opinion, given the current deficient and conflicting evidence.
机译:新鲜冷冻血浆(FFP)用于治疗大量出血。最近的审计表明,医生对FFP的了解不足,并且在重症监护中输注的FFP中有一半是不合适的。创伤是FFP的最大消费者之一。当前的创伤复苏指南建议FFP仅在经过实验室测试诊断后才纠正凝血病,通常是在已经存在明显的稀释性凝血病的情况下。支持这些指南的证据有限,出血仍然是创伤相关死亡的主要原因。最近的研究表明,凝血病发生在创伤的早期。一种新颖的早期配方驱动的止血复苏方法,建议在FFP与红细胞比例接近1:1的情况下,在大规模出血中早期解决凝血病。最近的回顾性报告表明,这种策略可显着降低死亡率,并且在重症监护中其应用正在逐步扩大至非创伤性出血。但是,辅助研究存在偏见,限制了对结果的解释。此外,后勤方面的考虑,包括对立即可用的通用供体AB血浆的需求,解冻后寿命短,潜在的浪费以及与输血相关的并发症,都对它的实施提出了挑战。本综述的重点是大出血中的FFP输血,并严格评估配方驱动复苏的证据,在当前证据不足和矛盾的情况下,为临床医生提供知情意见提供了资源。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号